Skip to main content
SpringerLink
Log in

Neuroprotection by selegiline and other MAO inhibitors

  • Conference paper
MAO — The Mother of all Amine Oxidases

Part of the book series: Journal of Neural Transmission. Supplement ((NEURAL SUPPL,volume 52))

Summary

A proposal for the nomination of the father of monoamine oxidase inhibitors is presented. A brief history of the human clinical pharmacology of selegiline is considered including the results of two major prospective ongoing clinical trials and recent evidence on the effects of sustained selegiline therapy on postural blood pressures in parkinsonians is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Beringer K (1928) Über ein neues, auf das extrapyramidal-motorische System wirkendes Alkaloid (Banisterin). Nervenarzt 1: 265–275

    Google Scholar 

  • Birkmayer W, Riederer P, Youdim MBH, Linauer W (1975) The potentiation of the anti-akinetic effect after 1-dopa treatment by an inhibitor of MAO-B, Deprenyl. J Neural Transm 36: 303–326

    Article  PubMed  CAS  Google Scholar 

  • Birkmayer W, Knoll J, Riederer P, Youdim MBH, Harts V, Marton J (1985) Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson’s disease: a long-term study. J Neural Transm 64: 113–127

    Article  PubMed  CAS  Google Scholar 

  • Blaschko H, Richter D, Schlossmann H (1937) The inactivation of adrenaline. J Physiol (Lond) 90: 1–15

    CAS  Google Scholar 

  • Blaschko H, Richter D, Schlossmann H (1937) The oxidation of adrenaline and other amines. Biochem J 31: 2187–2196

    PubMed  CAS  Google Scholar 

  • Elsworth JD, Glover V, Reynolds GP, Sandler M, Lees AJ, Phuapradit P, Shaw KM, Stern GM, Kumar P (1978) Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the “cheese effect”. Psychopharmacology 57: 33–38

    Article  PubMed  CAS  Google Scholar 

  • Halpern L (1930) Ueber die Harminwirkung im Selbstversuch. Dtsch Med Wochenschr 56: 1252–1254

    Article  Google Scholar 

  • Hare MLC (1928) Tyramine oxidase. 1. A new enzyme system in the liver. Biochem J 22: 968–979

    CAS  Google Scholar 

  • Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467–469

    Article  PubMed  CAS  Google Scholar 

  • Knoll J (1978) The possible mechanisms of action of (—)-deprenyl in Parkinson’s disease. J Neural Transm 43: 177–198

    Article  PubMed  CAS  Google Scholar 

  • Knoll J, Ecsery Z, Kelemen K, Nievel JG, Knoll B (1965) Phenylpropylmethyl-propinylamine (E-250): a new spectrum psychic energizer. Arch Int Pharmacodyn 155: 154–164

    PubMed  CAS  Google Scholar 

  • Lees AJ, Shaw KM, Kohout L, Stern GM, Elsworth JD, Sandler M, Youdim MBH (1977) Deprenyl in Parkinson’s disease. Lancet ii: 791–795

    Article  Google Scholar 

  • Lewin L (1928) Untersuchungen uber Banisterin caapi Spr. Arch Exp Pathol Pharmakol 129: 133–149

    Article  CAS  Google Scholar 

  • Lewin L, Schuster P (1929) Ergebnisse von Banisterinversuchen an Kranken. Dtsch Med Wochenschr 55: 149

    Article  Google Scholar 

  • Mann J, Gershon S (1980) L-deprenyl, a selective monoamine oxidase inhibitor in endogenous depression. Life Sci 26: 877–882

    Article  PubMed  CAS  Google Scholar 

  • The Parkinson’s Disease Research Group of the UK (1993) Comparison of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson’s disease: three year interim report. BMJ 307: 469–472

    Article  Google Scholar 

  • The Parkinson’s Disease Research Group of the UK (1995) Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. BMJ 311: 1602–1607

    Article  Google Scholar 

  • The Parkinson’s Disease Research Group of the UK (1996) BMJ 312: 704–705 (letter)

    Google Scholar 

  • The Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 321: 1364–1371

    Article  Google Scholar 

  • The Parkinson Study Group (1996) Impact of Deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects not requiring levodopa. Ann Neurol 39: 29–36

    Article  Google Scholar 

  • The Parkinson Study Group (1996) Impact of Deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects requiring levodopa. Ann Neurol 39: 37–45

    Article  Google Scholar 

  • Reynolds GP, Elsworth JD, Blau K, Sandler M, Lees AJ, Stern GM (1978) Deprenyl is metabolised to methamphetamine and amphetamine in man. Br J Clin Pharmacol 6: 542–544

    Article  PubMed  CAS  Google Scholar 

  • Spruce R (1908) Notes of a Botanist on the Amazon and Ande, vol 11. Macmillan, London

    Google Scholar 

  • Udenfriend S, Witkop B, Redfield BG, Wiessbach H (1958) Studies with reversible inhibitors of monoamine oxidase: harmaline and related compounds. Biochem Pharmacol 1: 160–165

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Neurology, University College, London Hospitals, UK

    G. Stern

Authors
  1. G. Stern
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacology, The Bruce Rappaport Faculty of Medicine, Technion — Israel Institute of Technology, Haifa, Israel

    J. P. M. Finberg  & M. B. H. Youdim  & 

  2. Clinical Neurochemistry, Department of Psychiatry, University of Würzburg, Federal Republic of Germany

    P. Riederer

  3. Biochemistry Department, Trinity College, Dublin, Ireland

    K. F. Tipton

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Wien

About this paper

Cite this paper

Stern, G. (1998). Neuroprotection by selegiline and other MAO inhibitors. In: Finberg, J.P.M., Youdim, M.B.H., Riederer, P., Tipton, K.F. (eds) MAO — The Mother of all Amine Oxidases. Journal of Neural Transmission. Supplement, vol 52. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6499-0_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6499-0_12

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-83037-6

  • Online ISBN: 978-3-7091-6499-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation